1, company profile:
Sichuan Keruide Pharmaceutical Co., Ltd. was established in 2004, located in Zone A, West Industrial Park, Lu Xian County, Luzhou City, Sichuan Province. It is a national high-tech enterprise integrating scientific research, production and sales. There are two subsidiaries and 1 R&D center: Sino-US joint ventures-Sichuan Creed Hua Kai Pharmaceutical Co., Ltd., Luzhou Hongji Pharmaceutical Technology Co., Ltd. and Chengdu R&D Center of Sichuan Creed Hua Kai Pharmaceutical Co., Ltd. The company covers an area of 128 mu, with a registered capital of17.88 million yuan and existing assets of 100. Capsule, tablet and granule production line 1 piece. Annual production capacity: 800 million capsules, 400 million tablets and 654.38 billion bags of granules. The company has been rated as "Innovative Enterprise in Sichuan Province", "Growing Small and Medium-sized Enterprise in Sichuan Province", "Leading Small and Medium-sized Enterprise in Sichuan Province", "AA Credit Enterprise" and "Advanced Unit for Helping Poor Students", and has been rated as "Big Taxpayer" in Lu Xian County for 8 consecutive years.
Sichuan Keruide Hua Kai Pharmaceutical Co., Ltd. has a registered capital of RMB 654,380+005,500. The company is committed to the research and development and production of chemical raw materials, especially in the field of anti-tumor. 20 10 12, which successfully passed the FDA certification, is the first manufacturer of raw materials for human use in Sichuan province.
2, the main products and technical level
chemical agent
Lu Kang-tandospirone citrate capsule (exclusively listed in China, a Class B medical insurance product, specially designed to relieve anxiety), its technology has reached the international leading level.
Cleton-Tizanidine Hydrochloride Tablets (a new antispasmodic analgesic, exclusively marketed in Chinese mainland, is a Class B product of medical insurance, which is a specific drug for effectively relieving various chronic pains and hypertonia), and its technology has reached the international leading level.
Pipecuronium bromide for injection (domestic exclusive production, class B variety of medical insurance, muscle relaxation during general anesthesia).
Sodium valproate for injection (reducing the incidence of epilepsy after brain surgery, a broad-spectrum antiepileptic injection, the only intravenous antiepileptic preparation).
Pamidronate disodium for injection (medical insurance class B, the first choice for bone pain caused by cancer bone metastasis)
Chinese patent medicine preparation
Duanxueliu Capsule, Guanmaining Tablet, Duanxueliu Effervescent Tablet, Compound Qingguo Granule (sugar-free type) and Xinkeshu Granule (sugar-free type)
3. Newly developed products
Newly developed product: tizanidine hydrochloride orally disintegrating tablets
The latest drug for treating leukemia-Baixiaoan injection, etc.
Existing products: continuously improve technology and quality standards, form second-class patents, raise technical barriers, enhance competitiveness, develop new medical uses, form patents, and develop 1.6 new drugs. Cooperate with the hospital to carry out more perfect clinical research.
Second, the ability of independent innovation
1, technical personnel
The company has a strong R&D organization-Chengdu R&D Center of Sichuan Keruide Pharmaceutical Co., Ltd., and a young and highly educated R&D team. * * * There are 25 professionals engaged in pharmaceutical R&D, including 2 doctors and 8 masters. The rest have bachelor degree or above, with more than 5 years experience in R&D, and are familiar with various instrument analysis and method development.
2, research equipment and research and development funds, etc.
The center is equipped with a large number of advanced experimental equipment such as infrared spectrometer, high performance liquid chromatograph, gas chromatograph and ultraviolet spectrophotometer. The company invests more than 5 million yuan in R&D every year, accounting for about 6.5% of the sales revenue, and has established a set of perfect technological innovation management systems, such as the Measures for the Management of Scientific Research Funds, the Measures for the Management of Intellectual Property Rights, and the Measures for the Incentive of Technological Innovation.
3. Intellectual property rights and the current situation in Industry-University-Research
The company has applied for 23 patents, including patent 16 (8 invention patents, 2 utility model patents and 6 appearance patents). The company has established long-term cooperative relations with Sichuan University and Luzhou Medical College, and combined with Industry-University-Research, it has become the "teaching practice base" of Luzhou Medical College and the "youth employment and entrepreneurship practice base" of the Communist Youth League Committee.
Third, development planning.
The company will add 300 mu of land in Luzhou Pharmaceutical Industrial Park, and build a water needle workshop, an anti-tumor drug workshop, a chemical intermediate workshop, a new product incubation center and a modern pharmaceutical company. The total investment of the new project is 500 million yuan, which will be built in three phases. After the project is completed and put into production, it is estimated that the annual output will be 65.438+0.5 billion capsules, 2 billion tablets, 65.438+0.000 injections, 5,000 kilograms of chemical intermediates and 65.438+0.5 million kilograms of pharmaceutical intermediates, with an annual output value of 65.438+0.000 billion yuan and profits and taxes of 65.438+. 10 year, the output value reached 3 billion yuan, and the profit and tax was 450 million yuan.
The first phase of the project started construction in June 20 13, covering an area of 70 mu, with a total investment of1200,000 yuan. It mainly constructs water injection workshop, anti-tumor drug preparation workshop, freeze-dried powder injection workshop, chemical intermediate workshop, traditional Chinese medicine pretreatment and extraction workshop, etc. It is estimated that 5 10 varieties will be produced, reaching 80 million kinds of anti-tumor drugs, 2,000 kilograms of chemical intermediates, 5 million injections and 5,000 kilograms of traditional Chinese medicine extracts. It was completed and put into operation at the end of 20 14.
The second phase of the project covers an area of 150 mu with an investment of 250 million yuan. Build a modern pharmaceutical company, expand its business scope and scale, and equip it with a modern warehousing system and logistics system. It is planned that 20 15 will be completed and put into production. There are more than 1 000 sales staff in China, and more than 30 offices have been set up, with sales income exceeding 654,380+0 billion yuan.
The third phase of the project covers an area of 80 mu with an investment of10.30 billion yuan. It mainly builds international standardized preparation workshop, Chinese medicine preparation workshop, anti-tumor drug water injection workshop, freeze-dried powder injection workshop, new product incubation center, modern office and quality inspection building. , in line with the requirements of the FDA. It is planned to be completed and put into operation in 20 16.